News That Matters

Tag: drug

'To some, Maddie was just a junkie': Obituary gives new take on drug addiction

'To some, Maddie was just a junkie': Obituary gives new take on drug addiction

Health
Madelyn Linsenmeir was a mother, sister and friend, who was "hilarious, and warm, and fearless, and resilient." She was also an opioid addict. Linsenmeir was a drug addict for 12 years and, at what her sister said were some of her darkest points, she would sometimes panhandle for money. She lost custody of her young son because of her disease. On Oct. 7, the 30-year-old died in the hospital while in police custody, according to her sister, Kate O'Neill. O’Neill does not want Linsenmeir to be remembered for her addiction. Her surprisingly honest obituary she wrote for a local Vermont paper is getting widespread attention for its warmth and candor. “It is impossible to capture a person in an obituary, and especially someone whose adult life was largely defined by drug addict...
Vaccine, drug combo promising against HPV-related cancers

Vaccine, drug combo promising against HPV-related cancers

Health
Sept. 27 (UPI) -- Combining a tumor-specific vaccine with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to HPV, according to a phase II clinical trial. Participants were injected with the vaccine ISA101, which targets important peptides from a cancer-promoting HPV16 genotype of human papillomavirus, and nivolumab, a drug that blocks activation of PD-1 on T cells. The findings were published Thursday in the Journal of the Medical Association Oncology. "That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials, so these results will lead to larger, randomized clinical trials of this combination," principal investigator Dr. Bonnie Glisson, a professor of thoracic/head and neck...
NHS to save 'hundreds of millions' in landmark drug ruling

NHS to save 'hundreds of millions' in landmark drug ruling

Health
A landmark ruling against two leading drug companies could save the NHS "hundreds of millions" a year. The case centred on the treatment of patients with the eye condition, wet age-related macular degeneration (AMD).Twelve NHS bodies in the north east of England were offering patients the drug Avastin, a cheaper alternative to the licensed drug, Lucentis. Health bosses said the ruling may reduce the power of companies to fix prices. Drug company Novartis said they were "deeply disappointed" because patients were being asked to accept an unlicensed treatment to save the NHS money.David Hambleton, chief executive officer of NHS South Tyneside clinical commissioning group (CCG), one of the NHS groups involved in the case, welcomed ...
Researchers to test individualized drug cocktails for kids' brain tumors

Researchers to test individualized drug cocktails for kids' brain tumors

Health
Aug. 30 (UPI) -- Using genomic technology, researchers are planning a clinical trial of individualized drug cocktails to treat children with a form of malignant brain tumor. Researchers at the University of California San Francisco plan to treat up to 44 children and young adults with high-grade glioma at the UCSF Benioff Children's Hospital San Francisco and other sites in the 18-hospital Pacific Pediatric Neuro-Oncology Consortium network. "One of the pitfalls in identifying the drugs best suited for each child is that many therapies fail to cross the blood-brain barrier or have a high enough concentration to cause a biological effect," Dr. Michael Prados, a neuro-oncologist at UCSF Benioff Children's Hospitals and founder and co-project leader of PNOC, said in a press release. "We are ...
FDA approves first drug to treat rare corneal eye condition

FDA approves first drug to treat rare corneal eye condition

Health
Aug. 23 (UPI) -- The U.S. Food and Drug Administration approved the first medication to treat a rare eye disease affecting the cornea. Dompe farmaceutici SpA, an Italian bio-pharmaceutical company, can market and sell the brand name drug Oxervate to treat neurotrophic keratitis in the United States, the FDA said in a release Wednesday. The drug was approved by the European Medicines Agency in 2017. "While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in a press release. "In the past, it has often been necessary to turn to surgical interventions; these treatments are usually only palliative in this disease." ...